Decision coverage

A-7 Test coverage of S/W structure (decision coverage) is achieved. SAV Verification Results 11.14 ... 

Hayhurst, K., Veerhusen, D., 2001. In A Practical Approach to Modified Condition Decision Coverage, 20th Digital Avionics Systems Conference, Daytona Beach, Florida, USA, 14-18 October 2001. 

Independence (statement coverage, decision coverage, data and control coupling, executable object code and source code complies with low-level requirements, high- and low-level requirements comphance, accuracy and consistency)... 

Independence (modified condition decision coverage, executable object code robustness with low-level requirements, source code complied, with SAV architecture, accuracy and consistency, partitioning integrity, SAV architecture is compatible with high-level requirements and consistent)... 

Decision coverage (DC) implies that every entry and exit posting in the computer program has been evaluated, and evaluated for every possible outcome of every decision — all control and data flows exercised at least once. 

Modified condition/decision coverage (MCDC) implies that both statement and decision coverage have been achieved and that each condition in a decision has been evaluated for all outcomes and each condition in a decision is shown to independently affect a decision s outcome - aU control and data flows exercised to the extent that control flows are influenced by data flows. 

Hayhurst KJ, Veerhusen DS, Chilenski JJ, Rierson LK (2001) A practical tutorial on modified condition/decision coverage. National Aeronautics and Space Administration Jaffe MS, Busser R, Daniels D, Delseny H, Romanski G (2008) Progress report on some proposed upgrades to the conceptual software engineering underpinnings of DO-178B/ED-12B. Proc of the 3rd lET Int Syst Saf Conf... 

To make the process practical for community hospitals, this technology must be inexpensive and easily operated in the ED. Transmission of CT images to experienced radiologists for formal and final interpretation is essential for quality control and feedback. As a result, systems that permit remote decision-making by expert physicians reduce the manpower needed to provide acute stroke team coverage in ED without around-the-clock access to in-house stroke neurology. 

Biologic response modifiers (BRMs) are indicated in patients who have failed an adequate trial of DMARD therapy.1 BRMs may be added to DMARD monotherapy (i.e., methotrexate) or replace ineffective DMARD therapy.22 The decision to select a particular agent generally is based on the prescriber s comfort level with monitoring the safety and efficacy of the medications, the frequency and route of administration, the patient s comfort level or manual dexterity to self-administer subcutaneous injections, the cost, and the availability of insurance coverage.23 In general, BRMs should be avoided in patients with serious infections, demyelinating disorders (e.g., multiple sclerosis or optic neuritis) or heart failure.21... 

The coverage of permeability in this book is more comprehensive than that of solubility, lipophilicity, and ionization. This decision was made because permeability is not as thoroughly treated in the pharmaceutical literature as the other topics, and also because much emphasis is placed on the PAMPA in this book, which is indeed a very new technique [547] in need of elaboration. 

Our review of some regulatory decisions, based on risk information, has been a relatively superficial one, and has avoided many complicated legal and policy issues, to say nothing of the political warfare that may accompany some decisions. The review, though selective in its coverage, does reveal that regulators draw no single... 

---